BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

664 related articles for article (PubMed ID: 9701386)

  • 21. Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion.
    Keever-Taylor CA; Bredeson C; Loberiza FR; Casper JT; Lawton C; Rizzo D; Burns WH; Margolis DA; Vesole DH; Horowitz M; Zhang MJ; Juckett M; Drobyski WR
    Biol Blood Marrow Transplant; 2001; 7(11):620-30. PubMed ID: 11760150
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long term follow up after allogeneic stem cell transplantation for chronic myelogenous leukemia.
    Reiter E; Greinix HT; Brugger S; Keil F; Rabitsch W; Mannhalter C; Schwarzinger I; Höcker P; Fischer G; Dieckmann K; Hinterberger W; Linkesch W; Schneider B; Lechner K; Kalhs P
    Bone Marrow Transplant; 1998 Dec; 22 Suppl 4():S86-8. PubMed ID: 9916646
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors.
    Ayuk F; Diyachenko G; Zabelina T; Panse J; Wolschke C; Eiermann T; Binder T; Fehse B; Erttmann R; Kabisch H; Bacher U; Kröger N; Zander AR
    Exp Hematol; 2008 Aug; 36(8):1047-54. PubMed ID: 18456390
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
    Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
    Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bone marrow transplantation for chronic myelogenous leukemia: clinical outcomes.
    Enright H; Davies S; McGlave P
    Clin Transpl; 1994; ():283-93. PubMed ID: 7547549
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Allogeneic bone marrow transplantation in chronic myeloid leukemia. The clinical results and risk factors in 70 patients].
    Tomás JF; Peñarrubia MJ; García JA; Figuera A; Gómez-García de Soria V; Steegmann JL; Arranz R; Cámara R; Gabriel R; Vázquez L
    Med Clin (Barc); 1995 Nov; 105(16):605-11. PubMed ID: 8523939
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Matched unrelated donor marrow transplantation in patients with advanced acute leukemia.
    Greinix HT; Reiter E; Schulenburg A; Keil F; Lechner K; Fischer G; Rosenmayr A; Leitner G; Kalhs P
    Bone Marrow Transplant; 1998 Dec; 22 Suppl 4():S53-6. PubMed ID: 9916636
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Allogeneic bone marrow transplantation for chronic myeloid leukemia in childhood: a report from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).
    Millot F; Esperou H; Bordigoni P; Dalle JH; Michallet M; Michel G; Bourhis JL; Kuenz M; Blaise D; Garban F; Plouvier E; Rome A; Guilhot J; Guilhot F
    Bone Marrow Transplant; 2003 Nov; 32(10):993-9. PubMed ID: 14595387
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bone marrow transplants in chronic myelogenous leukemia: an overview of determinants of survival.
    McGlave P
    Semin Hematol; 1990 Jul; 27(3 Suppl 4):23-30. PubMed ID: 1695763
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allogeneic bone marrow transplantation for leukemia with marrow grafts treated by counterflow centrifugation.
    De Witte T; Schattenberg A; Preijers F; Raymakers R; Muus P; Wessels J
    Bone Marrow Transplant; 1993; 12 Suppl 3():S2-6. PubMed ID: 8124252
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prior treatment with alpha-interferon does not adversely affect the outcome of allogeneic BMT in chronic phase chronic myeloid leukemia.
    Zuffa E; Bandini G; Bonini A; Santucci MA; Martinelli G; Rosti G; Testoni N; Zaccaria A; Tura S
    Haematologica; 1998 Mar; 83(3):231-6. PubMed ID: 9573677
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term outcomes of HLA-matched sibling compared with mismatched related and unrelated donor hematopoietic stem cell transplantation for chronic phase chronic myelogenous leukemia: a single institution experience in China.
    Liu QF; Xu XJ; Chen YK; Sun J; Zhang Y; Fan ZP; Xu D; Jiang QL; Wei YQ; Huang F; Feng R; Liu XL; Xu B; Meng FY
    Ann Hematol; 2011 Mar; 90(3):331-41. PubMed ID: 20872002
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft.
    Lee CK; deMagalhaes-Silverman M; Hohl RJ; Hayashi M; Buatti J; Wen BC; Schlueter A; Strauss RG; Gingrich RD
    Bone Marrow Transplant; 2003 Jan; 31(2):121-8. PubMed ID: 12621494
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
    Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bone marrow transplantation in thalassemia major patients using "short" anti-thymocyte globulin therapy in Shiraz, Southern Iran.
    Zakerinia M; Khojasteh HN; Ramzi M; Haghshenas M
    Transplant Proc; 2005 Dec; 37(10):4477-81. PubMed ID: 16387149
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A retrospective comparison of allogeneic peripheral blood stem cell and bone marrow transplantation results from a single center: a focus on the incidence of graft-vs.-host disease and relapse.
    Ustün C; Arslan O; Beksaç M; Koç H; Gürman G; Ozçelik T; Yilmaz B; Ilhan O; Akan H; Ozcan M; Demirer T; Uysal A; Konuk N; Arat M; Dilek I; Celebi H; Coskun HS
    Biol Blood Marrow Transplant; 1999; 5(1):28-35. PubMed ID: 10232738
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of pretransplant interferon-alpha(IFN) treatment in the outcome of stem cell transplantation (SCT) from related donors in chronic myelogenous leukemia (CML): results from three Turkish transplant centers.
    Beksac M; Celebi H; Sargín D; Yalcin A; Topcuoglu P; Kalayoglu-Besisik S; Beyan C; Arslan O; Ozcan M; Gurman G; Ilhan O; Akan H
    Bone Marrow Transplant; 2003 May; 31(10):897-904. PubMed ID: 12748666
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bone marrow transplantation for chronic myeloid leukemia: the use of histocompatible unrelated volunteer donors.
    Mackinnon S; Hows JM; Goldman JM; Arthur CK; Hughes T; Apperley JF; Jones L; Batchelor JR; Brookes P; Catovsky D
    Exp Hematol; 1990 Jun; 18(5):421-5. PubMed ID: 2338131
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel approach to human leukocyte antigen-mismatched transplantation in patients with malignant hematological disease.
    Huang XJ; Han W; Xu LP; Chen YH; Liu DH; Lu J; Chen H; Zhang YC; Jiang Q; Liu KY; Lu DP
    Chin Med J (Engl); 2004 Dec; 117(12):1778-85. PubMed ID: 15603704
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bone marrow transplantation from partially HLA-mismatched family donors for acute leukemia: single-center experience of 201 patients.
    Mehta J; Singhal S; Gee AP; Chiang KY; Godder K; Rhee Fv Fv; DeRienzo S; O'Neal W; Lamb L; Henslee-Downey PJ
    Bone Marrow Transplant; 2004 Feb; 33(4):389-96. PubMed ID: 14716338
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.